Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC)

Authors:

Abdul Rafeh Naqash, Paul R. Walker, Mahvish Muzaffar, Rebecca Feldman, Maida Hafiz, Stephen V. Liu, Hirva Mamdani, Anokhi Patel, Hossein Borghaei, Nitika Sharma, Jorge J. Nieva, Yanis Boumber, Ari M. Vanderwalde, Patrick C. Ma, Ihab Azab, David Craig Portnoy, Li V. Yang, Alexander I. Spira, Nagla Fawzy Abdel Karim

Background

  • Early data suggests that cooccurring genetic events define biological heterogeneity in K-RAS mutant NSCLC, with K-RAS/ TP-53 co-mutated (KP) subset having potential therapeutic vulnerabilities to anti-PD-1 therapy with (A) improved response rates and (B) durable clinical benefit.
  • To explore the immunological basis for these findings, we evaluated the immune biomarker profile (TMB/PDL1) in KP mutant m-NSCLC using a large next-generation sequencing (NGS) dataset.

Download Publication